» Articles » PMID: 24886416

Functional Properties of the HIV-1 Long Terminal Repeat Containing Single-nucleotide Polymorphisms in Sp Site III and CCAAT/enhancer Binding Protein Site I

Overview
Journal Virol J
Publisher Biomed Central
Specialty Microbiology
Date 2014 Jun 3
PMID 24886416
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: HIV-1 gene expression is driven by the long terminal repeat (LTR), which contains many binding sites shown to interact with an array of host and viral factors. Selective pressures within the host as well as the low fidelity of reverse transcriptase lead to changes in the relative prevalence of genetic variants within the HIV-1 genome, including the LTR, resulting in viral quasispecies that can be differentially regulated and can potentially establish niches within specific cell types and tissues.

Methods: Utilizing flow cytometry and electromobility shift assays, specific single-nucleotide sequence polymorphisms (SNPs) were shown to alter both the phenotype of LTR-driven transcription and reactivation. Additional studies also demonstrated differential loading of transcription factors to probes derived from the double-variant LTR as compared to probes from the wild type.

Results: This study has identified specific SNPs within CCAAT/enhancer binding protein (C/EBP) site I and Sp site III (3 T, C-to-T change at position 3, and 5 T, C-to-T change at position 5 of the binding site, respectively) that alter LTR-driven gene transcription and may alter the course of viral latency and reactivation. The HIV-1 LAI LTRs containing the SNPs of interest were coupled to a plasmid encoding green fluorescent protein (GFP), and polyclonal HIV-1 LTR-GFP stable cell lines utilizing bone marrow progenitor, T, and monocytic cell lines were constructed and utilized to explore the LTR phenotype associated with these genotypic changes.

Conclusions: Although the 3 T and 5 T SNPs have been shown to be low-affinity binding sites, the fact that they can still result in effective HIV-1 LTR-driven gene expression, particularly within the TF-1 cell line, has suggested that the low binding site affinities associated with the 3 T C/EBP site I and 5 T Sp site III are potentially compensated for by the interaction of nuclear factor-κB with its corresponding binding sites under selected physiological and cellular conditions. Additionally, tumor necrosis factor-α and Tat can enhance basal transcription of each SNP-specific HIV-1 LTR; however, differential regulation of the LTR is both SNP- and cell type-specific.

Citing Articles

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.

Apetroaei M, Velescu B, Nedea M, Dinu-Pirvu C, Draganescu D, Faca A Biomedicines. 2024; 12(4).

PMID: 38672269 PMC: 11048092. DOI: 10.3390/biomedicines12040915.


Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications.

Zahedipour F, Zahedipour F, Zamani P, Jaafari M, Sahebkar A Virus Res. 2024; 341:199314.

PMID: 38211734 PMC: 10825633. DOI: 10.1016/j.virusres.2024.199314.


Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Mohamed H, Gurrola T, Berman R, Collins M, Sariyer I, Nonnemacher M Front Immunol. 2022; 12():816515.

PMID: 35126374 PMC: 8811197. DOI: 10.3389/fimmu.2021.816515.


Severe acute respiratory syndrome coronavirus 2 may exploit human transcription factors involved in retinoic acid and interferon-mediated response: a hypothesis supported by an analysis.

di Bari I, Franzin R, Picerno A, Stasi A, Cimmarusti M, Di Chiano M New Microbes New Infect. 2021; 41:100853.

PMID: 33680474 PMC: 7912353. DOI: 10.1016/j.nmni.2021.100853.


CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.

Sharma G, Sharma A, Bhattacharya M, Lee S, Chakraborty C Mol Ther. 2020; 29(2):571-586.

PMID: 33238136 PMC: 7854284. DOI: 10.1016/j.ymthe.2020.09.028.


References
1.
Connor R, Mohri H, Cao Y, Ho D . Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol. 1993; 67(4):1772-7. PMC: 240220. DOI: 10.1128/JVI.67.4.1772-1777.1993. View

2.
Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath P . The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996; 85(7):1135-48. DOI: 10.1016/s0092-8674(00)81313-6. View

3.
Folks T, Justement J, Kinter A, Schnittman S, Orenstein J, Poli G . Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol. 1988; 140(4):1117-22. View

4.
ROSS E, Rabson A, Englund G, Martin M . Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol. 1991; 65(8):4350-8. PMC: 248874. DOI: 10.1128/JVI.65.8.4350-4358.1991. View

5.
Corboy J, Buzy J, Zink M, Clements J . Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice. Science. 1992; 258(5089):1804-8. DOI: 10.1126/science.1465618. View